BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26970274)

  • 1. Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    Chen KE; Walker AM
    Cancer Lett; 2016 Jun; 375(2):293-302. PubMed ID: 26970274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.
    Favy DA; Rio PG; Vissac C; Maurizis JC; Bignon YJ; Bernard-Gallon DJ
    Anticancer Res; 2000; 20(3A):1703-4. PubMed ID: 10928095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1.
    Xie W; He Y; Huo D; Huang Y; Wu W
    Med Oncol; 2010 Dec; 27(4):1340-5. PubMed ID: 20013077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells.
    Wu W; Ginsburg E; Vonderhaar BK; Walker AM
    Cancer Res; 2005 Aug; 65(16):7509-15. PubMed ID: 16103106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
    Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
    Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
    Lu M; Arrick BA
    Oncogene; 2000 Dec; 19(54):6351-60. PubMed ID: 11175350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BARD1 regulates BRCA1-mediated transactivation of the p21WAF1/CIP1 and Gadd45 promoters.
    Fabbro M; Henderson BR
    Cancer Lett; 2008 May; 263(2):189-96. PubMed ID: 18243530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
    Somasundaram K; Zhang H; Zeng YX; Houvras Y; Peng Y; Zhang H; Wu GS; Licht JD; Weber BL; El-Deiry WS
    Nature; 1997 Sep; 389(6647):187-90. PubMed ID: 9296497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context.
    Gutzman JH; Rugowski DE; Nikolai SE; Schuler LA
    Oncogene; 2007 Sep; 26(43):6341-8. PubMed ID: 17438530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
    Girgert R; Hanf V; Emons G; Gründker C
    J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
    Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
    Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
    Sourvinos G; Spandidos DA
    Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1].
    Luo YQ; Mi MT; Wei N; Xu HX; Zhu JD
    Ai Zheng; 2004 Aug; 23(8):924-8. PubMed ID: 15301716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor.
    Chao CH; Chen CM; Cheng PL; Shih JW; Tsou AP; Lee YH
    Cancer Res; 2006 Jul; 66(13):6579-88. PubMed ID: 16818630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).
    Williamson EA; Wolf I; O'Kelly J; Bose S; Tanosaki S; Koeffler HP
    Oncogene; 2006 Mar; 25(9):1391-9. PubMed ID: 16331276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
    Friedrichsen BN; Galsgaard ED; Nielsen JH; Møldrup A
    Mol Endocrinol; 2001 Jan; 15(1):136-48. PubMed ID: 11145745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
    Hao L; ElShamy WM
    Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
    Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
    Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
    Kawai H; Li H; Chun P; Avraham S; Avraham HK
    Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.